scispace - formally typeset
J

Jonathan Noble

Researcher at National Institutes of Health

Publications -  7
Citations -  1015

Jonathan Noble is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Lung cancer & Survival rate. The author has an hindex of 5, co-authored 6 publications receiving 863 citations.

Papers
More filters
Journal ArticleDOI

Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21

Andrea Bezjak, +17 more
- 20 Aug 2006 - 
TL;DR: Eerrlotinib not only improves survival in previously treated patients with NSCLC, but also improves tumor-related symptoms and important aspects of QOL.
Journal ArticleDOI

Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study

Glenwood D. Goss, +19 more
- 20 Sep 2013 - 
TL;DR: Although the trial closed prematurely and definitive statements regarding the efficacy of adjuvant gefitinib cannot be made, these results indicate that it is unlikely to be of benefit.
Journal ArticleDOI

Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study

Glenwood D. Goss, +19 more
- 01 Jan 2010 - 
TL;DR: The addition of cediranib to carboplatin/paclitaxel results in improved response and PFS, but does not appear tolerable at a 30-mg dose.
Journal ArticleDOI

Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline.

Jonathan Noble, +3 more
- 01 Nov 2006 - 
TL;DR: Second-line or subsequent therapy with single-agent docetaxel, pemetrexed, or erlotinib offers patients a significant survival and QOL advantage.
Journal ArticleDOI

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Obbina Abani, +7885 more
- 03 Mar 2022 - 
TL;DR: In patients hospitalised with COVID-19, baricitinib significantly reduced the risk of death but the size of benefit was somewhat smaller than that suggested by previous trials.